晚期肝癌合并不同结核类型患者的免疫治疗效果及生存期对比  

Comparison of immunotherapy effect and survival time in patients with advanced liver cancer complicated with different types of tuberculosis

作　　者：李磊[1] Li Lei(Guangzhou Chest Hospital,Guangzhou,Guangdong 510030,China)

机构地区：[1]广州市胸科医院,广东广州510030

出　　处：《首都食品与医药》2025年第9期31-34,共4页Capital Food Medicine

基　　金：广东省卫生健康发展促进项目(编号:BJHA-CRP-056)。

摘　　要：目的 探讨晚期肝癌合并不同结核类型患者的免疫治疗效果及对生存期的影响。方法 回顾性分析我院收治的晚期肝癌合并结核患者29例,入选时间为2020年1月-2023年12月,其中A组(晚期肝癌合并活动性结核患者,19例)、B组(晚期肝癌合并陈旧性结核患者,10例),两组均接受免疫治疗,A组同时接受抗结核治疗。对比两组患者的临床疗效及生存期。结果 两组总有效率比较,无统计学差异(P>0.05)。治疗后、两组ALT、AST、TBIL水平均较治疗前降低(P<0.05),但两组间ALT、AST、TBIL水平比较,无显著差异(P>0.05)。A组中位总生存期(mOS)为3.0个月(95%CI0.8-5.2个月),B组mOS为2.3个月(95%CI0.1-6.7个月),两组比较,无统计学差异(P=0.941)。结论 对于晚期肝癌合并结核患者而言,抗结核治疗并不会对免疫治疗的疗效及患者生存期产生明显影响。Objective To investigate the effect of immunotherapy on survival of patients with advanced liver cancer complicated with different types of tuberculosis.Methods A retrospective analysis was performed on 29 patients with advanced liver cancer complicated with tuberculosis admitted to our hospital from January 2020 to December 2023,including group A(19 patients with advanced liver cancer complicated with active tuberculosis)and group B(10 patients with advanced liver cancer complicated with old tuberculosis),both groups received immunotherapy,and group A received anti-tuberculosis therapy at the same time.The clinical efficacy and survival time of the two groups were compared.Results There was no significant difference in total effective rate between the two groups(P>0.05).After treatment,the levels of ALT,AST and TBIL in 2 groups were lower than those before treatment(P<0.05),but there were no significant differences in ALT,AST and TBIL levels between 2 groups(P>0.05).The median Overall Survival(mOS)of group A was 3.0 months(95%CI 0.8-5.2 months),and that of group B was 2.3 months(95%CI 0.1-6.7 months),and there was no statistical difference between the two groups(P=0.941).Conclusion For patients with advanced liver cancer complicated with tuberculosis,anti-tuberculosis therapy has no significant effect on the efficacy of immunotherapy and the survival time of patients.

关 键 词：肝癌 结核 免疫治疗 生存期 

分 类 号：R735.7[医药卫生—肿瘤]